Mar 6 2019
The Heart.Org reports that the the Rivaroxaban and Apixaban reversal agent Andexxa (andexanet alpha) has earned conditional approval by the European Medicines Agency. Click or tap here for details.
Comments (0)
Anticoagulant Therapy
No comments here.